CorMedix Inc. to Present at the Cantor Global Healthcare Conference

Company Overview - CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases [3] - The company is commercializing its lead product DefenCath®, which received FDA approval on November 15, 2023 [3] - DefenCath was launched in inpatient settings in April 2024 and in outpatient settings in July 2024 [3] Upcoming Events - Management will participate in a fireside chat and investor meetings at the 2024 Cantor Healthcare Conference in New York from September 17 to 19, 2024 [1] - The fireside chat is scheduled for September 19, 2024, at 10:55 AM EDT [2] - A replay of the fireside chat will be available on the investor relations section of the company's website [2]